Search results for "Cardiovascular agent"

showing 10 items of 72 documents

Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre …

2017

Background Data on the clinical performance of bioresorbable scaffolds in patients with diabetes mellitus (DM) are still limited. The present study reported 1-year clinical outcomes associated with the use of everolimus-eluting bioresorbable vascular scaffolds (Absorb BVS; Abbott Vascular, Santa Clara, CA) in DM patients. Methods and Results This was a subanalysis from the GHOST-EU (Gauging coronary Healing with biOresorbable Scaffolding plaTforms in Europe) multicenter retrospective registry including patients treated with Absorb BVS between November 2011 and September 2014. In this study, a comparative analysis stratified according to DM was performed. The primary endpoint was target lesi…

Target lesionMaleTime Factorsmedicine.medical_treatmentCoronary Artery Disease030204 cardiovascular system & hematologyCoronary Angiography0302 clinical medicineRisk FactorsNuclear Medicine and ImagingAbsorbable ImplantsClinical endpoint030212 general & internal medicineMyocardial infarctionRegistriesdiabetesClinical performanceGeneral MedicineMiddle AgedThrombosisbioresorbable vascular scaffoldsclinical outcomesEuropeTreatment Outcomebioresorbable vascular scaffolds; clinical outcomes; diabetes; Radiology Nuclear Medicine and Imaging; Cardiology and Cardiovascular MedicineCardiologyFemaleRadiologyCardiology and Cardiovascular Medicinemedicine.medical_specialtyRevascularizationProsthesis Design03 medical and health sciencesPercutaneous Coronary InterventionInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansRadiology Nuclear Medicine and imagingIn patientEverolimusAgedRetrospective Studiesbusiness.industryCoronary ThrombosisCardiovascular Agentsmedicine.diseaseSurgerybusinessCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions
researchProduct

Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions

2017

Abstract Objectives The authors sought to investigate 1-year outcomes in patients treated with bioresorbable everolimus-eluting vascular scaffolds (BVS) for “long coronary lesions.” Background The present substudy derived from the GHOST-EU registry included 1,722 lesions in 1,468 consecutive patients, enrolled between November 2011 and September 2014 at 11 European centers. Methods The lesions were divided into 3 groups according to continuous BVS length: 1) shorter than 30 mm; 2) between 30 and 60 mm; and 3) longer than 60 mm. Primary device-oriented endpoint (target lesion failure [TLF]) was defined as a combination of cardiovascular death, target vessel myocardial infarction, or clinical…

Target lesionmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPercutaneous coronary intervention030204 cardiovascular system & hematologymedicine.diseaseSurgeryCoronary artery diseaseLesion03 medical and health sciences0302 clinical medicineCoronary thrombosisInterquartile rangeCardiovascular agentMedicine030212 general & internal medicineMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function.

2008

Aim Drug-eluting stents are widely used to prevent restenosis but are associated with late endothelial damage. To understand the basis for this effect, we have studied the consequences of a prolonged incubation with rapamycin on the viability and functions of endothelial cells. Methods and results Human umbilical vein or aorta endothelial cells were exposed to rapamycin in the absence or in the presence of tumour necrosis factor α (TNFα). After a 24 h-incubation, rapamycin (100 nM) caused a significant cell loss associated with the increase of both apoptosis and necrosis, as quantified by propidium iodide staining, caspase 3 activity, and lactate dehydrogenase release. Rapamycin also impair…

Time FactorsPhysiologyApoptosismTORC1Polymerase Chain Reactionchemistry.chemical_compoundCell MovementStress FibersMicroscopy ConfocalCaspase 3TOR Serine-Threonine KinasesNitric Oxide Synthase Type IIIRibosomal Protein S6 Kinases 70-kDaUp-RegulationEndothelial stem cellmedicine.anatomical_structureBiochemistryCardiology and Cardiovascular MedicineE-SelectinEndotheliumNitric Oxide Synthase Type IIICell SurvivalBlotting WesternEnzyme-Linked Immunosorbent AssayBiologyMechanistic Target of Rapamycin Complex 1Nitric OxideTacrolimusNecrosisTheophyllinePhysiology (medical)medicineHumansImmunoprecipitationViability assayPropidium iodideProtein kinase BAdaptor Proteins Signal TransducingSirolimusDose-Response Relationship DrugL-Lactate DehydrogenaseTumor Necrosis Factor-alphaEndothelial CellsProteinsCardiovascular AgentsRegulatory-Associated Protein of mTORMolecular biologyRapamycin-Insensitive Companion of mTOR ProteinchemistryMultiprotein ComplexesTOR Serine-Threonine KinasesCarrier ProteinsProtein KinasesTranscription FactorsCardiovascular research
researchProduct

Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients.

2009

Comment in Timing of antihypertensive therapy and circadian blood pressure pattern. [Hypertension. 2009] Timing of antihypertensive therapy and circadian blood pressure pattern. Almirall J, Martínez-Ocaña JC, Comas L. Hypertension. 2009 Jun; 53(6):e41; author reply e42. Epub 2009 May 4. Dipping comes of age: the importance of nocturnal blood pressure. [Hypertension. 2009]. Dipping comes of age: the importance of nocturnal blood pressure. O'Brien E. Hypertension. 2009 Mar; 53(3):446-7. Epub 2009 Jan 26.Nondipping in patients with hypertension. [Hypertension. 2009] Ambulatory blood pressure (BP) monitoring has become useful in the diagnosis and management of hypertensive individuals. In addit…

cardiovascular risk factorsMale:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Cardiovascular Agents::Antihypertensive Agents [Medical Subject Headings]Blood Pressure:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Cohort Studiescircadian blood pressure patternFactores de riesgo cardiovascularPrevalenceRegistries:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]Blood Pressure Monitoring AmbulatoryMiddle AgedCircadian Rhythm:Phenomena and Processes::Physiological Phenomena::Chronobiology Phenomena::Periodicity::Circadian Rhythm [Medical Subject Headings]AmbulatoryHypertension:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Monitoring Physiologic::Monitoring Ambulatory::Blood Pressure Monitoring Ambulatory [Medical Subject Headings]CardiologyFemaleCohort studyAdultmedicine.medical_specialtyAmbulatory blood pressurenocturnal blood pressure dip:Check Tags::Male [Medical Subject Headings]:Diseases::Cardiovascular Diseases::Vascular Diseases::Hypertension [Medical Subject Headings]Diabetes mellitusInternal medicine:Phenomena and Processes::Circulatory and Respiratory Physiological Phenomena::Cardiovascular Physiological Phenomena::Hemodynamics::Blood Pressure [Medical Subject Headings]:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]Internal MedicinemedicineHumansCircadian rhythm:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Linear Models [Medical Subject Headings]Risk factorAntihypertensive AgentsAgedbusiness.industrymedicine.diseaseObesitySurgerycircadianBlood pressure:Check Tags::Female [Medical Subject Headings]Spain:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings]Linear Models:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries [Medical Subject Headings]businessHypertension (Dallas, Tex. : 1979)
researchProduct

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology …

2019

Aims The aim of this study was to determine whether the Joint European Societies guidelines on secondary cardiovascular prevention are followed in everyday practice. Design A cross-sectional ESC-EORP survey (EUROASPIRE V) at 131 centres in 81 regions in 27 countries. Methods Patients (<80 years old) with verified coronary artery events or interventions were interviewed and examined ≥6 months later. Results A total of 8261 patients (females 26%) were interviewed. Nineteen per cent smoked and 55% of them were persistent smokers, 38% were obese (body mass index ≥30 kg/m2), 59% were centrally obese (waist circumference: men ≥102 cm; women ≥88 cm) while 66% were physically active <30 min 5…

cardiovascular risk factorsMaleCardiac & Cardiovascular SystemsHeart diseaseEpidemiologymedicine.medical_treatmentHealth StatusEUROASPIRE ; cardiovascular risk factors ; guidelines ; lifestyle ; secondary preventionRisk Reduction Behavior*HSM CARRisk FactorsSecondary PreventionARTERY-DISEASEMyocardial infarctionEUROASPIREguidelinesDiet / adverse effectsRegistriesCardiovascular Diseases / physiopathology1102 Cardiorespiratory Medicine and HaematologyHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*Smoking / epidemiologySmokingHealthy Lifestyle*Middle AgedPREVALENCEEuropeCardiovascular Diseases / diagnosisTreatment OutcomeCardiovascular DiseasesCardiovascular Agents / therapeutic use*LDL Cholesterol LipoproteinsFemaleEurope / epidemiologyCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary preventionmedicine.medical_specialtylifestyleSmoking / adverse effectsCardiovascular risk factorsHEART-DISEASERisk AssessmentLOW-INCOME COUNTRIESLife Style*Cardiovascular Diseases / prevention & control*Cardiovascular preventionmedicineJournal ArticleHumansHealthy Lifestyleddc:610Risk factorLife StyleAgedCardiovascular Diseases / epidemiologyScience & TechnologyTask forcebusiness.industryCardiovascular AgentsSMOKING-CESSATIONProtective Factorsmedicine.diseaseDietEUROASPIRE Investigators*Cross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEFamily medicineHealth Care SurveysCardiovascular System & CardiologySmoking cessationPatient ComplianceHydroxymethylglutaryl-CoA Reductase InhibitorsSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCE
researchProduct

The Chemistry of the [1,2,3]Triazolo[1,5-a]pyridines: An Update

2010

Publisher Summary This chapter discusses the recent advancement in the chemistry of [1,2,3] triazolo[1,5-a]pyridines. It describes new discoveries in the physical properties and theoretical chemistry, focusing on synthesis of [1,2,3]triazolo[1,5-a]pyridine system, synthesis of novel aryltriazolopyridines, chiral ligands from [1,2,3]triazolo[1,5-a]pyridines, pyridylcarbene formation from triazolopyridines, ring-chain isomerization on [1,2,3]triazolo[1,5-a]pyridines, and novel pyridylcarbonylpyridines. All triazolopyridines have interesting ligand properties to form polynuclear complexes with different metal ions. X-ray single-crystal studies, magnetic, photo-magnetic, and colorimetric measur…

chemistry.chemical_compoundchemistryComputational chemistryCubaneStereochemistryLigandIntramolecular forcePyridineCardiovascular agentTheoretical chemistryAntiferromagnetismIsomerization
researchProduct

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.

2013

Contains fulltext : 118153.pdf (Publisher’s version ) (Open Access) Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted dr…

medicine.medical_specialtyCombination therapyPharmacologyAntiviral AgentsDrug interactionsTelaprevirTelaprevirchemistry.chemical_compoundPharmacotherapyAnti-Infective AgentsBoceprevirOpiate Substitution TreatmentmedicineHumansHypnotics and SedativesHypoglycemic AgentsPharmacokineticsSummary of Product CharacteristicsIntensive care medicineAdverse effectPolypharmacyBoceprevirHepatologybusiness.industryHCV therapyCardiovascular AgentsHepatitis C ChronicAntidepressive AgentsBuprenorphinechemistryCardiovascular agentHepatitis C virus infectionDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsPoverty-related infectious diseases Infectious diseases and international health [N4i 3]businessImmunosuppressive AgentsMethadonemedicine.drug
researchProduct

The impact of chocolate on cardiovascular health

2011

Cardiovascular disease is the leading determinant of mortality and morbidity in women. Functional foods are attracting interest as potential regulators of the susceptibility to disease. Supported by epidemiological evidence, chocolate has emerged as a possible modulator of cardiovascular risk. Chocolate, or cocoa as the natural source, contains flavanols, a subclass of flavonoids. The latter years have witnessed an increasing number of experimental and clinical studies that suggest a protective effect of chocolate against atherogenesis. Oxidative stress, inflammation, and endothelial function define three biological mechanisms that have shown sensitivity to chocolate. Moreover, the consumpt…

medicine.medical_specialtyFlavonolsmedicine.medical_treatmentCardiovascular healthPhysiologyDiseaseDark chocolateGeneral Biochemistry Genetics and Molecular BiologyfoodFunctional foodFunctional FoodmedicineAnimalsHumansInsulinWhite chocolateInflammationCacaomedicine.diagnostic_testbusiness.industryInsulinObstetrics and GynecologyCardiovascular AgentsPlatelet ActivationLipidsfood.foodSurgeryCardiovascular DiseasesNatural sourceEndothelium VascularPlant PreparationsbusinessLipid profilePhytotherapyMaturitas
researchProduct

Nitric oxide synthases: regulation and function

2011

Nitric oxide (NO), the smallest signalling molecule known, is produced by three isoforms of NO synthase (NOS; EC 1.14.13.39). They all utilize l-arginine and molecular oxygen as substrates and require the cofactors reduced nicotinamide-adenine-dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and (6R-)5,6,7,8-tetrahydrobiopterin (BH(4)). All NOS bind calmodulin and contain haem. Neuronal NOS (nNOS, NOS I) is constitutively expressed in central and peripheral neurons and some other cell types. Its functions include synaptic plasticity in the central nervous system (CNS), central regulation of blood pressure, smooth muscle relaxation, and vasodila…

medicine.medical_specialtyNitric Oxide Synthase Type IIIEndotheliumNeovascularization PhysiologicNitric Oxide Synthase Type IIVasodilationNitric Oxide Synthase Type IReviewArginineNitric OxideEndothelial NOSNitric oxideMicechemistry.chemical_compoundEnosInternal medicineRenin–angiotensin systemmedicineAnimalsHumansbiologybusiness.industryCardiovascular AgentsGenetic Therapybiology.organism_classificationBiopterinIsoenzymesNitric oxide synthaseEndocrinologymedicine.anatomical_structurechemistryCardiovascular DiseasescGMP-specific phosphodiesterase type 5biology.proteinEndothelium VascularHydroxymethylglutaryl-CoA Reductase InhibitorsNitric Oxide SynthaseCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine

2016

In the last decades, many factors thought to be associated with the atherosclerotic process and cardiovascular events have been studied, and some of these have been shown to correlate with clinical outcome, such as arterial stiffness, endothelial dysfunction and immunoinflammatory markers. Arterial stiffness is an important surrogate marker that describes the capability of an artery to expand and contract in response to pressure changes. It can be assessed with different techniques, such as the evaluation of PWV and AIx. It is related to central systolic pressure and it is an independent predictor of cardiovascular morbidity and mortality in hypertensive patients, type 2 diabetes, end-stage…

medicine.medical_specialtyPathologyEndotheliumPopulation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineAnimalsHumansPlatelet activationEndothelial dysfunctioneducationInflammationPharmacologyeducation.field_of_studySurrogate endpointbusiness.industryCardiovascular AgentsArteriesmedicine.diseasemedicine.anatomical_structureBlood pressureCardiovascular DiseasesCardiovascular agentArterial stiffnessCardiologyEndothelium Vascularbusiness030217 neurology & neurosurgeryCurrent Pharmaceutical Design
researchProduct